TrialJournal of hematology & oncology2014

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.

Mark Thalgott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.